Tesamorelin (Egrifta, and the later reformulations Egrifta SV and Egrifta WR) is indicated to reduce excess visceral (abdominal) adipose tissue in patients with HIV-associated lipodystrophy a condition in which antiretroviral therapy and HIV itself drive an abnormal accumulation of deep abdominal fat
The phentermine component acts as an appetite suppressant, while topiramate potentially reduces food cravings, making it a doubly effective strategy for managing weight
It is also not for use in individuals with a history of pancreatitis or those with type 1 diabetes
In a major development in obesity treatment, Eli Lilly and Company has announced that its next-generation experimental weight-loss drug, retatrutide, has delivered striking results in a late-stage clinical trial
As we age, however, our natural production of these vital messengers often declines